Biognosys’ mass spectrometry-based proteomics solutions enable research with unprecedented precision, depth, and scale. Powered by our cutting-edge technology, extensive facility, and state-of-the-art data analytics, we provide deep, large-scale insights on the molecular phenotype, enabling breakthrough discoveries and bringing life science to a new level.
Biognosys is the leading inventor and developer of mass spectrometry-based proteomics solutions. Our unprecedented proteome coverage and sample throughput enable simultaneous quantification of thousands of proteins across thousands of samples.
Biognosys operates one of the largest high-end mass spectrometry laboratories worldwide for Large-Scale Discovery Proteomics contract research. Our industry-leading sample throughput enables us to handle large volumes of samples while maintaining unprecedented precision and depth.
Thanks to our biological expertise and data analytics capabilities we are the proteomics knowledge provider of choice. Having analyzed a vast amount of proteomics data across various species and biological matrices, we have an extensive understanding of the proteome. Building on our technology, we provide excellent Protein Data Science and comprehensive Biomedical Evidence and Insights.
Biomarkers play a vital role in precision medicine, from the development of novel targeted therapies and diagnostics to clinical biomarker applications. Biognosys’ Tiss [...]
For many studies, biofluid samples are more easily available than tissue samples. Our Biofluid Biomarker Discovery service enables deep and reproducible quantification of [...]
What is large-scale discovery proteomics? Proteomics has the potential to bring about transformative changes in our understanding of biology and the therapeutic targets linked[...]READ MORE
Through this development, Biognosys continues to advance industry standards for specificity and depth in[...]READ MORE
Biognosys announces an expansion of its facilities with an additional office and laboratory 900 square meters (9687 sqft) site in the Bio-Technopark at Wagistrasse 18, Schlieren,[...]READ MORE
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today the appointment of Karel Novy, PhD as Chief Operating[...]READ MORE
Precision oncology requires a detailed molecular understanding of tumor biology, which is best characterized by the study of the proteome. Biognosys has developed a high[...]READ MORE
Obesity is a leading world problem and severe risk factor for cardiovascular disease, liver diseases like NAFLD or NASH and type 2 diabetes. Together with Nestlé we have analyzed[...]READ MORE